Inflammation
Showing NaN - NaN of 2
Cardiovascular Risk, Chronic Kidney Disease, Inflammation Trial in Worldwide (Ziltivekimab, Placebo (ziltivekimab))
Recruiting
- Cardiovascular Risk
- +2 more
- Ziltivekimab
- Placebo (ziltivekimab)
-
Birmingham, Alabama
- +768 more
Dec 23, 2022
Inflammation, Rheumatoid Arthritis Trial in Worldwide (NNC0109-0012, )
Terminated
- Inflammation
- Rheumatoid Arthritis
- NNC0109-0012
- placebo
-
Huntsville, Alabama
- +163 more
Sep 3, 2018